DBV Technologies' Drug in the FDA Approval Process
This section highlights FDA-related milestones and regulatory updates for drugs developed by DBV Technologies (DBVT).
Over the past two years, DBV Technologies has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Viaskin. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Viaskin Peanut (EPITOPE) FDA Regulatory Events
Viaskin Peanut (EPITOPE) is a drug developed by DBV Technologies for the following indication: Peanut-allergic toddlers ages 1 to 3 years.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Viaskin Peanut (EPITOPE)
- Announced Date:
- February 10, 2026
- Indication:
- Peanut-allergic toddlers ages 1 to 3 years
Announcement
DBV Technologies announced that the company will present additional data for the VIASKIN® Peanut Patch in children ages 4-7 years from the positive VITESSE Phase 3 study at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting, taking place in Philadelphia, PA February 27-March 2, 2026.
AI Summary
DBV Technologies will present additional data from the positive VITESSE Phase 3 study of the VIASKIN® Peanut Patch in children ages 4–7 at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting in Philadelphia, PA, Feb 27–Mar 2, 2026. The oral abstract titled “VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age” is scheduled for Feb 28, 2026, 2:15–2:25pm ET in the Clinical Science in Food Allergy session and will be presented by David Fleischer, MD.
DBV will also host a product theater on Feb 28, 10:00–10:30am ET, titled “Epicutaneous Immunotherapy (EPIT): Shaping the Future of Pediatric Food Allergy Treatment,” with panelists Hugh Sampson, MD; Katherine Anagnostou, MD, MSc, PhD; and S. Shahzad Mustafa, MD. Attendees can visit DBV at booth #1527 to learn more about EPIT and the VIASKIN Peanut Patch, early intervention, and how these approaches may change peanut allergy management.
Read Announcement- Drug:
- Viaskin Peanut (EPITOPE)
- Announced Date:
- March 24, 2025
- Indication:
- Peanut-allergic toddlers ages 1 to 3 years
Announcement
DBV Technologies announced that in a Written Responses Only to the Company's Type D IND meeting request, the U.S. Food and Drug Administration (FDA) agreed with the Company's proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in 4 – 7-year-olds will be sufficient to support a Biologics License Application (BLA) filing in this age group.
AI Summary
DBV Technologies announced that the FDA has agreed—in a Written Responses Only to the Company’s Type D IND meeting request—that the safety exposure data from the VITESSE Phase 3 study will be sufficient for a Biologics License Application (BLA) for the Viaskin peanut patch in children aged 4 to 7 years. This agreement means that the supplemental COMFORT Children safety study is no longer required, allowing DBV to accelerate its BLA submission timeline to the first half of 2026. The decision is based on robust safety data generated from active treatment participants and those who crossed over to the open-label extension, covering over 500 children on Viaskin peanut patch treatment at the time of submission. The FDA’s alignment with DBV is seen as a major step forward in providing a new treatment option for children with peanut allergies.
Read Announcement
DBV Technologies FDA Events - Frequently Asked Questions
As of now, DBV Technologies (DBVT) has not received any FDA approvals for its therapy in the last two years.
In the past two years, DBV Technologies (DBVT) has reported FDA regulatory activity for Viaskin Peanut (EPITOPE).
The most recent FDA-related event for DBV Technologies occurred on February 10, 2026, involving Viaskin Peanut (EPITOPE). The update was categorized as "Data Presentation," with the company reporting: "DBV Technologies announced that the company will present additional data for the VIASKIN® Peanut Patch in children ages 4-7 years from the positive VITESSE Phase 3 study at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting, taking place in Philadelphia, PA February 27-March 2, 2026."
Currently, DBV Technologies has one therapy (Viaskin Peanut (EPITOPE)) targeting the following condition: Peanut-allergic toddlers ages 1 to 3 years.
More FDA Event Resources from MarketBeat
Companies With Recent FDA Events
FDA Event Stage Terminology & Abbreviation Guide
- NDA: New Drug Application
- ANDA: Abbreviated New Drug Application
- sNDA: Supplemental New Drug Application
- BLA: Biologics License Application
- sBLA: Supplemental Biologics License Application
- FDA Approved: Approved by the FDA
- EMA: European Medicines Agency
- CE Mark: European Union Certification
- NMPA: China National Medical Products Administration
- MHLW: Japanese Ministry of Health
- FDA Meeting: Consultation with FDA
- Pre-IND: Pre-Investigational New Drug Meeting
- Breakthrough Therapy: Special FDA designation for promising therapies
- Fast Track: Accelerated FDA approval pathway
- Orphan Drug: Designation for rare disease treatments
- RPD: Rare Pediatric Disease Designation
- RMAT: Regenerative Medicine Advanced Therapy
- DSMB Review: Data Safety Monitoring Board Review
- IDMC Review: Independent Data Monitoring Committee
- MAA: MHRA Marketing Authorization Application
- RTF: Refusal to File (Rejected Application)
- 510(k): FDA Clearance for Medical Devices
- Rolling Submission: Staggered regulatory review process
FDA progress for NASDAQ:DBVT last updated on 2/10/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
